Liraglutide Injection Shortage

• • Victoza subcutaneous injection, Novo Nordisk, 6 mg/mL, 3 mL pen injector, 3 count, NDC 00169-4060-13
  • Liraglutide subcutaneous injection, Teva, 6 mg/mL, 3 mL pen injector, 2 count, NDC 00480-3667-20
  • Liraglutide subcutaneous injection, Teva, 6 mg/mL, 3 mL pen injector, 3 count, NDC 00480-3667-22

• • Meitheal launched liraglutide injection in April 2025.
  • Novo Nordisk has Victoza on shortage due to manufacturing delays.
  • Novo Nordisk has Saxenda available.
  • Teva did not provide a reason for the shortage.

• • Saxenda subcutaneous injection, Novo Nordisk, 6 mg/mL, 3 mL pen injector, 5 count, NDC 00169-2800-15
  • Victoza subcutaneous injection, Novo Nordisk, 6 mg/mL, 3 mL pen injector, 2 count, NDC 00169-4060-12
  • Liraglutide subcutaneous injection, Meitheal Pharmaceuticals, 6 mg/mL, 3 mL pen injector, 2 count, NDC 71288-0563-85
  • Liraglutide subcutaneous injection, Meitheal Pharmaceuticals, 6 mg/mL, 3 mL pen injector, 3 count, NDC 71288-0563-84

Estimated Resupply Dates

• • Novo Nordisk has Victoza 6 mg/mL 3 mL pens in 3 count presentations on back order and the company estimates a release date in mid-August 2025.
  • Teva has liraglutide 6 mg/mL in 2 count and 3 count presentations on back order and the company estimates a release date in early-August 2025.